The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The price of Procept BioRobotics Corp (NASDAQ: PRCT) closed at $52.05 in the last session, up 0.42% from day before closing price of $51.83. In other words, the price has increased by $0.42 from its previous closing price. On the day, 0.59 million shares were traded. PRCT stock price reached its highest trading level at $53.25 during the session, while it also had its lowest trading level at $51.985.
Ratios:
We take a closer look at PRCT’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.77 and its Current Ratio is at 7.63. In the meantime, Its Debt-to-Equity ratio is 0.28 whereas as Long-Term Debt/Eq ratio is at 0.28.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Piper Sandler on August 11, 2023, initiated with a Overweight rating and assigned the stock a target price of $42.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 18 ’24 when Zadno Reza sold 5,391 shares for $48.83 per share. The transaction valued at 263,243 led to the insider holds 241,319 shares of the business.
Waters Kevin sold 1,024 shares of PRCT for $50,002 on Mar 18 ’24. The EVP, CFO now owns 102,149 shares after completing the transaction at $48.83 per share. On Mar 18 ’24, another insider, Nouri Alaleh, who serves as the EVP, CLO, CORP. SEC. of the company, sold 441 shares for $48.83 each. As a result, the insider received 21,534 and left with 62,472 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PRCT now has a Market Capitalization of 2675380480 and an Enterprise Value of 2476555264. For the stock, the TTM Price-to-Sale (P/S) ratio is 19.48 while its Price-to-Book (P/B) ratio in mrq is 9.41. Its current Enterprise Value per Revenue stands at 18.184 whereas that against EBITDA is -23.505.
Stock Price History:
The Beta on a monthly basis for PRCT is 0.98, which has changed by 0.8231174 over the last 52 weeks, in comparison to a change of 0.24191546 over the same period for the S&P500. Over the past 52 weeks, PRCT has reached a high of $54.79, while it has fallen to a 52-week low of $24.83. The 50-Day Moving Average of the stock is 5.51%, while the 200-Day Moving Average is calculated to be 31.02%.
Shares Statistics:
According to the various share statistics, PRCT traded on average about 489.69K shares per day over the past 3-months and 578980 shares per day over the past 10 days. A total of 50.77M shares are outstanding, with a floating share count of 48.57M. Insiders hold about 4.70% of the company’s shares, while institutions hold 89.22% stake in the company. Shares short for PRCT as of 1713139200 were 5357470 with a Short Ratio of 10.94, compared to 1710460800 on 4117825. Therefore, it implies a Short% of Shares Outstanding of 5357470 and a Short% of Float of 14.360000000000001.
Earnings Estimates
Currently, 8.0 analysts are dedicated to thoroughly evaluating and rating the performance of Procept BioRobotics Corp (PRCT) in the stock market.On average, analysts expect EPS of -$0.56 for the current quarter, with a high estimate of -$0.49 and a low estimate of -$0.61, while EPS last year was -$0.63. The consensus estimate for the next quarter is -$0.53, with high estimates of -$0.49 and low estimates of -$0.6.
Analysts are recommending an EPS of between -$1.93 and -$2.06 for the fiscal current year, implying an average EPS of -$2.0. EPS for the following year is -$1.52, with 9.0 analysts recommending between -$1.05 and -$1.78.
Revenue Estimates
According to 9 analysts, the current quarter’s revenue is expected to be $41.58M. It ranges from a high estimate of $43.2M to a low estimate of $40.7M. As of the current estimate, Procept BioRobotics Corp’s year-ago sales were $24.4MFor the next quarter, 9 analysts are estimating revenue of $49.75M. There is a high estimate of $50.26M for the next quarter, whereas the lowest estimate is $49.23M.
A total of 9 analysts have provided revenue estimates for PRCT’s current fiscal year. The highest revenue estimate was $211.3M, while the lowest revenue estimate was $209.7M, resulting in an average revenue estimate of $210.18M. In the same quarter a year ago, actual revenue was $136.19MBased on 9 analysts’ estimates, the company’s revenue will be $295.65M in the next fiscal year. The high estimate is $305.92M and the low estimate is $269.9M.
